Morning Briefing
Summaries of health policy coverage from major news organizations
FDA Green-Lights New Breast Cancer Drug From Roche
Stat: FDA Approves New Breast Cancer Drug, A New Option For Some Patients
The Food and Drug Administration on Monday approved a new breast cancer drug from Roche, teeing up the launch of a medicine that the Swiss company has said could become its top-selling product ever. (Joseph, 11/16)
On treatments for Alzheimer's —
The Washington Post: The First Pill To Slow Alzheimer’s Could Come From An Unexpected Place
Alzheimer’s drug research is littered with failures. But this week, clinicians delivered some unexpectedly positive news, courtesy of a Viagra-like pill that has been repurposed for the brain disease. The drug, already sold as Mvix in South Korea for erectile dysfunction, slowed mental decline in a year-long global trial of more than 1,500 people with early Alzheimer’s — but only in those who weren’t already taking other dementia drugs. (Dolgin, 11/17)
The New York Times: An Intriguing Approach To Slow Alzheimer’s Shows Mixed Results
The largest trial to date of a headset device that delivers flickering light and sound in an attempt to slow the progression of Alzheimer’s has delivered mixed results. The device is based on the theory that audiovisual stimulation can evoke brainwave responses that might help preserve neurological function and clear waste from the brain. The idea is appealing because, if such a treatment works, it could provide an accessible non-drug alternative to Alzheimer’s medications that are expensive and carry significant safety risks. (Belluck, 11/16)
On weight loss drugs —
The Baltimore Sun: Maryland Approves First-In-The-Nation Payment Limits For Ozempic, Jardiance
The Maryland Prescription Drug Affordability Board voted unanimously Monday to approve final regulations setting the state’s first upper payment limits on two prescription drugs, Jardiance and Ozempic, in a first-in-the-nation effort to reduce what state and local governments pay for some prescription drugs. (Breunig and Metz, 11/16)
Healthcare Dive: CVS White Paper Aims To Pressure Drugmakers To Lower GLP-1 Prices
GLP-1s would save employers money in the long term if priced at $350 a month or less, the company found. “I would love to see this pressure [drugmakers] to bring down prices to something rational,” CMO Amy Compton-Phillips said. (Parduhn, 11/16)
The Washington Post: GLP-1 Weight-Loss Drugs Have Big Cons, Even If Serious Problems Are Rare
Todd Engel runs his hand along the dining room table, pushed against a wall to help guide him through his Maryland home. On a good day, he can distinguish a shadow from the darkness. Engel, 63, is legally blind. He can no longer drive and had to leave the job he loved operating heavy equipment. Most days, he stays home. (Eunjung Cha and Wu, 11/16)
Stat: Newer GLP-1 Drugs Could Lead To Fights Over Global Access
Over the past few months, lower-cost generic versions of the blockbuster GLP-1 drug semaglutide, which is sold as Wegovy by Novo Nordisk for combating obesity, started to become available in some countries and will soon arrive in still others. Meanwhile, the pharmaceutical industry is racing to develop newer GLP-1 medicines that, to varying degrees, are forecast to be more effective, cause fewer side effects, and are easier to administer. (Silverman, 11/16)
The Hill: DJ Khaled Shares He Lost 90 Pounds With Help Of GLP-1 Drug Wegovy
DJ Khaled shared the reason why he took control of his health. The producer revealed he lost 90 pounds since last year with the help of the weight loss drug Wegovy. “The motivation was there, the inspiration was there, working out and trying to eat better, but I needed help,” he told People magazine. “We live for our kids, and our kids make us live. So, I have to do my part.” Khaled admitted he had to “keep it real” with himself about his weight and spoke to a doctor about taking a GLP-1. (Grant, 11/13)
More pharmaceutical news —
The Examination: Tobacco Firms Test Melt-In-Your-Mouth Alternatives To Nicotine Pouches
The latest product from the tobacco industry is a flavorful nicotine tablet that melts in your mouth, allowing users to get a buzz as discreetly as popping a mint — and amping up concerns that products to replace cigarettes are too appealing to kids and teens. (Kranhold, 11/17)
MedPage Today: CBD Didn't Top Placebo For Behavioral Problems In Kids With Intellectual Disability
Cannabidiol (CBD) was no better than placebo for treating severe behavioral problems in kids with intellectual disabilities, a randomized clinical trial in Australia showed. (Robertson, 11/16)
CIDRAP: Shoulder Injuries Rare But Slightly More Common After COVID Vaccines Than Flu Shots, Study Finds
After receiving a COVID-19 vaccine, shoulder injuries are rare, but they may occur more frequently than they do after receiving a flu vaccine, according to a new, large-scale study published in JAMA Internal Medicine. Shoulder injury related to vaccine administration (SIRVA) is a condition that can occur after vaccination in the upper arm (deltoid muscle). SIRVA is defined as shoulder symptoms in the vaccination arm that begin within seven days of vaccination, last for at least 30 days, and appear to have no other possible cause. SIRVA was added to the National Vaccine Injury Compensation Program injury table in 2017. (Bergeson, 11/16)